InvestorsHub Logo
Followers 138
Posts 22891
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Sunday, 06/02/2019 11:58:48 AM

Sunday, June 02, 2019 11:58:48 AM

Post# of 458809
The company is well positioned to achieve key clinical readouts

Catalysts to Drive Value for AVXL:

1) Phase 2a – Reported 148-week data at CTAD 2018 scientific meeting

2) Phase 2b/3 clinical trial in Alzheimer’s disease – ongoing

3) Phase 2 clinical trial in Parkinson’s disease dementia (PDD) – ongoing

4) Phase 2 clinical trial in Rett syndrome (RTT) – ongoing

5) Topline data Phase 2 Parkinson’s disease dementia (PDD)

6) Topline data Phase 2 Rett syndrome (RTT)

7) Clinical data publications in 2019

8) New indications and licensing opportunities


https://www.anavex.com/wp-content/uploads/2019/04/Anavex-Presentation-April-2019.pdf

Good luck and GOD bless,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News